News

Back to All Articles

Spine Team Texas First In Area to Implement New Therapy for Spine Pain

9/17/2015

Spine Team Texas is pleased to announce the first implantation in North Texas of the Senza® spinal cord stimulator (SCS) by Amit Darnule, M.D., on a patient at Spine Team Texas Southlake. The Senza SCS system, which delivers Nevro's proprietary HF10™ therapy (Nevro Corporation, Menlo Park, California), is a recently FDA-approved spinal cord stimulator that has demonstrated superior results compared to traditional SCS for the treatment of back and leg pain in a large multicenter study in the United States.

“I’m honored to be the first spine pain physician in North Texas to offer this promising new technology to patients with chronic spine pain,” says Dr. Darnule, Spine Team Texas spine pain anesthesiologist, fellowship-trained in spine pain management. “The results of the SENZA-RCT have shown that this therapy offers more pain relief than traditional therapy, and I'm excited to
offer HF10 therapy as an option for our patients.”

Over 100 million people in the United States suffer from common chronic pain conditions, and chronic pain is the primary cause of adult disability in the U.S. The majority of these pain conditions are felt in the back or legs. There are a variety of treatment options for chronic pain that range from medications to surgical interventions.

Spinal cord stimulation (SCS) represents another option to treat chronic pain. It involves the delivery of electrical signals to the spinal cord in order to alter pain signals to the brain. The electrical pulses are delivered by small electrodes on leads that are placed near the spinal cord and are connected to a compact, battery-powered generator implanted under the skin. SCS is a reversible therapy that has helped hundreds of thousands of people experience relief from chronic pain.

In May, Nevro’s Senza SCS system, which is the only SCS system that delivers HF10 therapy, was approved by the FDA. HF10 therapy is the only SCS therapy: approved by FDA with superiority labeling; indicated by FDA to deliver pain relief without paresthesia (a constant tingling sensation that is the basis of traditional SCS); and approved by FDA to be used without patient restrictions on motor vehicle operation while receiving therapy. The Senza system is the only implantable SCS system approved by FDA with labeling for 3T conditional MRI compatibility.

For more information on the Senza system and HF10 therapy, see Nevro.com.

Download the full press release (PDF)

Back to All Articles